The Evolving Treatment Paradigm of Chronic Lymphocytic Leukemia

Development of effective new drugs in therapy of chronic lymphocytic leukemia (CLL) became possible only after the importance of the role of B-cell antigen receptor (BCR) in leukemia cell survival and proliferation was recognized by clinicians and pharmaceutical companies. There are several key enzymes in the downstream pathways of BCR which when inhibited by a drug can induce death of the leukemic cell and can also stop its proliferative ability. Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, and idelalisib , an inhibitor of PI 3-Kinase are two such new drugs which already have shown dramatic therapeutic activity in patients with relapsed/refractory CLL.

Video Comments

Log in to post a comment about this video.

Video Options

    • Add to Bookmarks